Press Release

Betta Pharmaceuticals' subsidiary XCovery and STADA reach an exclusive licensing and supply agreement for ensartinib in MENA

- Xcovery and STADA enter into licensing-and-supply agreement for oncology molecule ensartinib in 14 MENA countries
- Collaboration covers Saudi Arabia, Lebanon, Jordan, Bahrain, the United Arab Emirates, Kuwait, Oman, Qatar, Iraq, Algeria, Morocco, Tunisia, Egypt and Libya
- Partnership furthers Xcovery's strategy to bring novel small-molecule oncology treatments to patients and clinicians around the world, while strengthening STADA's position as a go-to-partner for specialty medicines in the MENA region

Miami, US/Bad Vilbel, Germany – 25 November 2026 – Xcovery Holdings, Inc. ("Xcovery"), a subsidiary of Betta Pharmaceuticals Co., Ltd. and STADA MENA DWC LLC ("STADA MENA"), an entity under Germany's STADA Group, have entered into a licensing-and-supply agreement, granting STADA MENA the exclusive rights to ensartinib hydrochloride (hereinafter referred to as "ensartinib") across 14 countries in the Middle East and North Africa (MENA).

Under the terms of the agreement, Xcovery has granted STADA MENA an exclusive license covering 14 countries, namely Saudi Arabia, Lebanon, Jordan, Bahrain, the United Arab Emirates, Kuwait, Oman, Qatar, Iraq, Algeria, Morocco, Tunisia, Egypt and Libya. The licensed rights include rights to marketing authorizations, importation, promotion, distribution and commercial sale. STADA MENA will pay Xcovery an undisclosed upfront sum and potential milestones and will purchase finished ensartinib capsules from Xcovery.

Executive Board: Peter Goldschmidt (CEO) / Miguel Pagan Fernandez / Boris Döbler / Bryan Kim
Chairman of the Supervisory Board: Dr. Günter von Au

Ensartinib is a novel, potent, and highly selective next-generation anaplastic lymphoma kinase (ALK) inhibitor, co-developed by Betta Pharmaceuticals and its subsidiary Xcovery. In November 2020, ensartinib was first approved for marketing in China as a treatment for ALK-positive non-small cell lung cancer (NSCLC).

In addition, ensartinib has been approved in the European Union, by the U.S. Food and Drug Administration (FDA), and by the Pharmaceutical Administration Bureau of the Macao Special Administrative Region (Macao SAR), China. Preparations for marketing authorization procedures are underway throughout the MENA region.

STADA Executive Vice-President of Emerging Markets, Stéphane Jacqmin, commented: "Adding a novel cancer treatment to our offering in the MENA region offers strong synergies with our existing Specialty portfolio in the region, not least with molecules such as trabectedin and bortezomib. This collaboration with Betta serves as further evidence that STADA is increasingly a go-to-partner across Specialty, Generics and Consumer Healthcare in the MENA region."

Shizhe Ding, Chairman Assistant, Betta Pharmaceuticals, said: "We are delighted to see another milestone achieved in ensartinib's global layout. The ALK-targeted therapy market in the Middle East and North Africa has reached a certain scale and holds sound growth potential. STADA MENA has in-depth insights into local pharmaceutical markets, while Xcovery possesses the complete R&D, manufacturing and supply-chain system for ensartinib. We look forward to both parties bringing their respective strengths into full play to accelerate the launch and commercialization of ensartinib across the Middle East and North Africa, so as to benefit more overseas oncology patients."

Li Mao, Member of the Board of Directors and CEO, Xcovery, said: "Ensartinib has demonstrated favourable efficacy and safety profiles across multiple clinical studies, delivering a new therapeutic option for patients with ALK-positive NSCLC. Moving forward,

Xcovery will draw on its mature global quality management system and work closely with STADA MENA to guarantee the production and sustained supply of finished ensartinib capsules. Together we aim to improve ensartinib's accessibility in the Middle East and North Africa, address diverse clinical needs of local oncology patients and bring survival benefits to more patients."

About STADA & STADA MENA

The STADA Group is headquartered in Bad Vilbel, Germany. The group focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA sells its products in over 100 countries. In financial year 2025, STADA achieved group sales of € 4,296 million. As of 31 December 2025, STADA employed 11,670 people worldwide. STADA MENA DWC LLC is STADA's regional hub based in Dubai, responsible for the Group's pharmaceutical operations in the Middle East and North-Africa region with proven capabilities in local registration, market access and commercialization.

About Betta Pharmaceuticals

Betta Pharmaceuticals Co., Ltd. was established in 2003 and is headquartered in Hangzhou, Zhejiang. It is a national high-tech pharmaceutical company founded by a team of talented high-level overseas returnees. The company focuses on the research and development (R&D) of innovative drugs with independent intellectual property rights and integrates R&D, manufacturing, and sales. Betta Pharmaceuticals was listed on the Shenzhen Stock Exchange in November 2016 (stock code: 300558.SZ). The company currently has nine commercialized products, supported by an integrated platform driven by the four engines of in-house R&D, marketing and sales, strategic collaboration, and innovation ecosystem. Leveraging Betta Dreamworks and a pharmaceutical industry fund, the company is committed to building an innovation ecosystem and helping more scientists achieve their dreams of entrepreneurship and innovation.

About Xcovery

Xcovery is Betta Pharmaceuticals' U.S.-based subsidiary dedicated to developing more effective and less-toxic therapeutics for patients living with advanced-stage cancers. By collaborating with global partners, Xcovery strives to develop small-molecule targeted oncology therapies with improved efficacy and safety, and actively explores solutions to address cancer-treatment resistance. Xcovery's product pipeline includes multiple innovative drug candidates such as ensartinib and vorolanib.

Executive Board: Peter Goldschmidt (CEO) / Miguel Pagan Fernandez / Boris Döbler / Bryan Kim
Chairman of the Supervisory Board: Dr. Günter von Au

STADA information for journalists

STADA Arzneimittel AG - Media Relations
Stadastrasse 2-18, 61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-165
E-Mail: press@stada.com
Or visit us via our website at https://www.stada.com/media/newsroom
Follow @StadaGroup on LinkedIn

STADA information for capital market participants

STADA Arzneimittel AG - Investor & Creditor Relations
Stadastrasse 2-18, 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-mail: ir@stada.de
Or visit us via our website at https://www.stada.com/investor-relations/

Xcovery/Betta Pharmaceuticals Contact:

Corporate Communications
Tel: +1 561 835 9356
E-Mail: info@xcovery.com

Medical and Safety Information Inquiries
Tel: +1 866 367 2268
E-Mail: medical.info@xcovery.com

Executive Board: Peter Goldschmidt (CEO) / Miguel Pagan Fernandez / Boris Döbler / Bryan Kim
Chairman of the Supervisory Board: Dr. Günter von Au